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Abstract. 
Several multivariable risk prediction models have been developed to asses an 
individual’s risk of developing specific cancers. Such models can be used in a variety of 
settings for prevention, screening and guiding investigations and treatments. Models 
aimed at predicting future disease risk that contains lifestyle factors may be of 
particular use for targeting health promotion activities at an individual level. This type 
of cancer risk prediction is not yet available in the UK. We have adopted the approach 
used by the well-established U.S. derived "YourCancerRisk" model  for use in the UK 
population which allow users to quantify their individual risk of developing individual 
cancers relative to the population average risk.  The UK version of YourCancerRisk" 
computes 10 year cancer risk estimates for 11 cancers utilising UK figures for 
prevalence of risk factors and cancer incidence.  Since the prevalence of risk factors and 
the incidence rates for cancer are different between the US and the UK population, this 
UK model provides more accurate estimates of risks for a UK population.   Using an 
example of breast cancer and data from UK Biobank cohort we demonstrate that the 
individual risk factor estimates are similar for the US and UK populations. Assessment 
of the performance and validation of the multivariate model predictions based on a 
binary score confirm the model’s applicability. The model can be used to estimate 
absolute and relative cancer risk for use in Primary Care and community settings and is 
being used in the community to guide lifestyle change. 
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Introduction. 
Over recent years, there has been a growth in the development of risk prediction 
models for cancer and other diseases (1-6).  These models provide a range of estimates 
of future risk of developing disease for applications in prevention, screening, diagnosis 
and treatment. Most of them are disease specific.  In general, risk algorithms include 
phenotypic information such as sex, age, and lifestyle factors. Some algorithms may also 
allow for the incorporation of emerging “omics” based factors and other biomarkers (7).   
   
Few cancer risk prediction models have included the modifiable risk components such 
as physical activity, diet and smoking.  One such model that has been developed for the 
US is the "YourCancerRisk" model which has been used as a tool for education as well as 
providing an approach to quantifying the effects of changing key lifestyle exposures. 
This was subsequently expanded into "YourDiseaseRisk" (8) which extends the range of 
endpoints to include 12 of the commonest types of cancers in the USA and 6 other 
chronic diseases (e.g., chronic bronchitis, stroke, emphysema, heart disease, diabetes, 
and osteoporosis).  The model was validated for ovarian, colon and pancreatic cancers 
in the U.S in Nurses’ Health Study and the US Health Professionals cohorts.  The results 
show the model to be well calibrated for ovarian and colon cancer in women and 
pancreatic cancer in men and moderately calibrated for colon cancer in men. 
Discriminatory accuracy for pancreatic cancer showed a concordance index of 0.72, and 
for colon cancer in men and women concordance indices were  0.71, 0.67 respectively) 
(9).  
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The “YourDiseaseRisk” model aims to predict the risks for individuals (aged 40 and 
above) of developing the 12 cancers relative to the general population. Uniquely, the 
approach adopted to develop such models involved extensive systematic reviews of 
existing studies and finding a consensus of expert opinions to identify risk factors and to 
the summarise the level of evidence as “definite”, “probable” and “possible” causes of 
cancer.  Risk points were then allocated according to the strength of the causal 
association and summed. Population average risk of cancer and cumulative 10-year risk 
were obtained from the US SEER data (10).  Finally, individual ranking relative to the 
population average was determined.   
The “YourDiseaseRisk” online tool has been available in the US since 2000.  It is offered 
as an educational tool and in 2005, the site recorded 54 million hits with 6.2 million 
page views. It was first hosted at Harvard University and, in 2007, transitioned to the 
Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of 
Medicine (CITE Siteman/Wash U/ BJH only)(8).   
 
The focus of this paper is to describe the steps taken to adapt the "YourDiseaseRisk" 
models focused on cancers for the UK population for use in Primary Care and 
community based settings.  We also assess the utility of the approach by scoring the 
suggested risk factors in the UK Biobank cohort. 
 
We have used the adapted UK version of the "YourDiseaseRisk" models (8) in a pilot 
study that used individual interviews to assess participants’ understanding and 
preferences for how such information is offered (publication in press).  These results 
will be presented elsewhere.   
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Materials and Methods. 
Cancer Risk models development. 
We adapted the YourDiseaseRisk models for 11 cancers using the UK data.  The 11 
cancers chosen were lung, prostate, breast, kidney, bladder, colon, skin, stomach, 
pancreatic, uterine and ovarian cancer.  Cervical cancer was not included as it required 
participants to disclose information on sexual history which was considered too 
sensitive. 
 
In general terms, the information required to develop prediction models are: 1) the 
identified list of risk factors for inclusion; 2) point estimates of the relative risk for each 
risk factor; and 3) population prevalence for each of the exposures.  To be able to 
compare individual risk to the population, further information such as cancer incidence 
by 10 year age bands is required.   
 
Comparison of relative risk (RR) between the US and the UK. 
To illustrate the comparative RRs between the two populations, we used the UKBiobank 
national cohort and analysed the RRs for breast cancer.  The UKBiobank female cohort 
consists of 273,467 women with age ranged between 40-69 years when recruited.  
Participants were enrolled in the UK Biobank from April, 2007, to July, 2010, from 21 
assessment centres across England, Wales, and Scotland using standardised 
procedures(11). The UK Biobank study was approved by the North West Multi-Centre 
Research Ethics Committee and all participants provided written informed consent to 
participate in the UK Biobank study. To date, the cohort has been followed up for 6 
years.  We computed RRs adjusted only for age.  The results are presented in table 6. 
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Model validation-an example.  
To demonstrate model validation, we selected breast cancer risk prediction as an 
example.  The UKBiobank cohort was used for the validation exercise.  For breast cancer 
cases, we used ICD10, ICD9 and self-reported codes (verified by the UKBiobank health 
professionals) and only incident cases were included in the analysis.  For controls, we 
used 2 comparison groups. Firstly only those subjects with no coded record in ICD10, 
ICD9 of cancer and secondly the coded with no cancer and no other self-reported illness.  
The total number of incident breast cancer cases was 3,378 and the total number of 
non-cancer controls was 235,603 or healthy controls was 59,731.   We coded all 
variables (except Tamoxifen/Raloxifene usage as such data was not available) present 
in the breast cancer risk prediction model based on presence or absence of the exposure 
for each individual as illustrated in Table 3.  To demonstrate the validity of the 
combined risk factors identified for the model we calculated the area under the curve of 
the model based on including all factors scored as a binary variable and generated 
calibration plots -the observed and expected proportions compare within the groups 
formed by the Hosmer-Lemeshow test.  All analyses were performed using STATA 14 
(12). 
 
Results. 
To develop the UK version of the “YourDiseaseRisk” models we have assumed that the 
risk factors for these cancers in the US and UK are the same and have obtained the list of 
risk factors and point estimates of relative risk for each risk factor from the US 
“YourDiseaseRisk” models. Since the "YourDiseaseRisk" model was first developed 
more than a decade ago and to ensure we use the most updated version, we started the 
process by extracting risk factors for each cancer from the "YourDiseaseRisk" online 
Cancer Research. 
on June 2, 2017. © 2017 American Association forcancerpreventionresearch.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on May 30, 2017; DOI: 10.1158/1940-6207.CAPR-16-0288 
8 
 
version(8) (Step 1).  Once we created a list of risk factors for each cancer, we assigned 
point estimates of relative risk (RR) for each factor (Step 2). These point estimates of 
RR’s were extracted from the original publication (13, 14), however if any factors did 
not have any cited value, we performed a literature search to obtain any missing 
estimates.  To maintain consistency across RR values, we used figures from publications 
by the Colditz study group and those with a cohort study design (examples of references 
are depicted in Table 1).  For example, as the multivitamin factor was not listed in the 
original article, we therefore chose and applied a RR of 0.7 from Zhang et al (15). 
 
As the original report applied RRs from compiling evidence from the US cohort studies 
over a period of time, it is important to justify the use of the RRs published by Colditz et 
al(14) in the UK models.  We demonstrated the similarities/variations of risks between 
the two populations (US and UK). To do this we have presented as an example the 
relative risks for breast cancer derived from the UKBiobank study (Table 2). The 
majority of the point estimates are similar and convert to the same risk score when 
using values in Table3.  The two exceptions were for multivitamin use and physical 
activity where the protective effects for both of these factors were less pronounced in 
the UK as compared to the US estimate. 
 
To obtain the population prevalence (step 3) for each of the exposures we then 
reviewed the literature on the UK prevalence of each factor for men and women for all 
11 cancers.  The criteria for publication selection included a) UK prevalence data from 
National surveys (16) or prevalence derived from large cohort studies representative of 
the general population in the UK, or b) if no data were available from those sources, 
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information/figures from cohort studies in European countries.  As an example, the 
colon cancer risk factors, RR and references chosen for prevalence are shown in Table 1. 
 
Computing risk scores. 
Once information on the UK prevalence of each risk factor was obtained, we then 
applied a score to each risk factor using the same scheme as presented in the original 
paper (summary as shown in Table 3). 
This risk score is used to compute two further scores – the population average risk 
score and an individual risk score relative to the population average.  The population 
average score is calculated by multiplying the risk score of each factor by the population 
prevalence of that particular factor.  To prevent negative scores, we chose the direction 
of each risk factor to make the population average score the highest possible. Taking 
physical activity, for example, the prevalence of carrying out 3 or more hours of total 
leisure-time physical activity per week in the UK population is 23%.  This figure means 
that 77% of the population do not do physical activity regularly at this particular level. 
When we apply a prevalence of 77% then the assigned score instead of being -10 (for 
those who are doing regular exercise) will be +10.  This conversion allows us to 
demonstrate the change in the individual risk score following any change in factors that 
are modifiable.  Summation of these scores produces the average population score.   
The risk score for a given individual relative to the population average is based on 
presence or absence of each factor.  An example is illustrated in Table 4.  The 
summation of scores for each risk factor for an individual provides the total risk score 
for a particular person  That total risk score is then divided by the average population 
score to give an individual index which is relative to population score (35/27= 1.3).  As 
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mentioned earlier, participants can see how their risk changes if they adopt suggested 
behaviours, for example by choosing to do regular exercise the total score for the 
individual illustrated in Table 4 can be reduced by 10 points (from 35 to 25), making 
their index score relative to the population reduced from 1.3 to 0.8. This calculation 
aims to illustrate to each individual the effect of a particular lifestyle or behaviour 
change leading to cancer risk reduction. 
 Conversion of individual index score to 5-category cancer level of risk. 
The index score for an individual can then be further transformed into a level of risk.  A 
numeric factor indicative of the strength of the risk level is assigned to the individual 
index score (Table 5). This is done to give an average value of the range of individual 
index scores as a single numeric estimate that reflects the risk level.   
For the individual in Table 3, for example, the individual index score is 1.3, which is 
equivalent to “above average risk” and gives a numeric factor of 1.5. 
10 Year estimated cancer risk. 
To enable estimation of an individual’s 10 year estimated cancer risk we calculated the 
average 10 year estimated risk for different ages and sexes of the UK population for all 
11 cancers.  We used the “Current Probability” method proposed by Esteve et al in 1994 
(17).  This method uses a life-table approach for calculating the risk of developing 
cancer, and takes into account the likelihood of dying from other causes. The method 
also requires information on deaths from all causes for each age-group. This method 
provides estimate of the 10 year risk of cancer. 
We obtained age- and sex-specific cancer incidence and mortality rates and numbers 
from  Cancer Research UK (18) and age- and sex-specific data on all-cause mortality 
Cancer Research. 
on June 2, 2017. © 2017 American Association forcancerpreventionresearch.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on May 30, 2017; DOI: 10.1158/1940-6207.CAPR-16-0288 
11 
 
from the Office of National Statistic (ONS) which are available online (19).  The 
following shows the specific data used for the calculation: 
1. The annual number of cancer deaths (cancer mortality for males and females); data 
from CRUK 2010-2012. 
2. The annual number of (registered) cancer cases for males and females; data from 
CRUK 2009-2011. 
3. The annual number of deaths (all-cause mortality for males and females); data from 
ONS 2011. 
4. The size of the mid-year population for males and females; data from ONS 2011. 
From this data we computed 10-year cancer risk for each cancer in males and females in 
10 year age bands from birth to over 80 years.  
Individual estimate 10 year cancer risk. 
Assuming the individual in Table 4 is a 40-year-old woman, the average 10-year risk of 
breast cancer (age 40-49) is 1.45% in the next 10 years (Table 6).  Multiplying this 
figure by the numeric factor of 1.5 (Table 4) will give a risk of 2.2% (above the 
population average) or approximately 1 case in 45 women. 
Example of Breast cancer risk prediction model performance and validation 
based on binary scoring of risk factors. 
The AUC for breast cancer risk prediction model based on utilising a binary score for 
each available risk factor in the UKBiobank dataset was 0.58 (95%C.I 0.57-0.60) for a 
comparison group of controls with no cancer and 0.64 (95%C.I 0.63-0.66) for a 
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comparison group of controls with no cancer or other illnesses.    Model calibration 
curves for both comparisons also suggested both models calibrated well (Figure 1).  
Discussion. 
The “YourDiseaseRisk” model has been developed using three key data including an 
estimate of relative risk of each risk factor, the prevalence figure of exposure in the 
population and the 10 year estimated cancer risk.  These figures can be acquired 
through literature review, National data archives or other organisations that compile 
these data publically (20).   
The “YourDiseaseRisk” site has been launched since 2000 and update/review of 
information is an ongoing process.  The model is an educational tool and can be used for 
cancer prevention in clinics, community settings, or by individuals simply seeking 
information on their own.  The popularity of “YourDiseaseRisk” is reflected by the large 
number of hits or page views.   
We have adopted their methodology and applied it to build a UK version and to 
demonstrate the applicability of the approach for other populations as well.  The main 
strengthen of the approach is the use of large population based studies to estimate the 
parameters needed to generate the model. 
To demonstrate the relative validity of the approach we chose breast cancer as an 
exemplar. We have demonstrated that the quantitative estimates of the individual risk 
factors apply to current UK population using data from the UKBiobank study. 
Furthermore we performed a model validation of the combined risk factors using a 
binary scoring system and the results suggests such a model is reasonably calibrated 
and has moderate discriminatory power (0.58 for a comparison group of controls with 
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no cancer and 0.64 (95%C.I 0.63-0.66) for a comparison group of controls with no 
cancer or other illnesses).  The prediction performance of a fully specified model using 
the point estimates of each risk factor rather than a binary value is likely to be higher as 
it will be derived from more precise estimates of their individual effect. Directly 
comparative data is not yet available in the UKBiobank for all parameters to undertake 
such analyses. 
 There are many breast cancer risk prediction models but only a few that contained 
epidemiological factors and most have similar predictive capabilities (21-30).  The 
majority of these models are extended versions of the Gail model(23).  They have been 
shown to have good calibration but moderate discrimination ranging from 0.56-0.89 
with few having been assessed in external validation analysis (23, 28, 31, 32).  Colditz el 
al, further reported an AUC of 0.64 (95%C.I 0.62–0.66) in their extended validation 
study using data from the Nurses' Health Study (32).  The validation exercise, based on 
breast cancer example presented here, supports the conclusion that the model can be 
used in the UK population when the prevalence of risk factors is substituted with the UK 
figures.   
There are, however, potential limitations to the approach that need to be taken into 
consideration. Firstly, although we were systematic in our literature reviews to obtain 
data on the point estimate RRs for risk factors missing from the original published 
“YourDiseaseRisk” model and the prevalence of all risk factors in the UK population, the 
studies we have chosen may not provide the most accurate estimates. Secondly, we 
have assumed that the prevalence of each risk factor does not change with age, that the 
risk associated with each risk factor is the same across all ages and both sexes, and that 
the risk factors do not interact with each other. These assumptions were also made in 
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the development of the “YourDiseaseRisk” models but, as noted in that report (14), may 
result in misclassification of risk for exposures across large age ranges and 
underestimate possible synergistic effects of exposures such as alcohol and smoking.  As 
for the “YourDiseaseRisk” models, therefore, these models should be considered as a 
guide for assessing an individual’s risk of cancer in the UK rather than a precise 
estimate.  
 Risk prediction models are widely used for many diseases.  With the concept that some 
cancers can be preventable, the “Your Disease risk” model developed by Colditz et al 
(14) provides a good platform because their model is based on modifiable factors that 
have been scrutinised and carefully selected by a panel of experts.  The approach has 
wide utility in allowing for the rapid development of models for educational purposes. 
In this paper we have described how we have adapted that model to produce a UK 
version for 11 cancers using data from the UK population.  We are now using the model 
in the community in the UK.   Going forwards we will evaluate how the tool affects 
perceptions of risk, how to best present the risk, and how the public understands their 
individual risk. This information will then inform future studies in the community 
exploring the potential for the use of this model to promote lifestyle change.  Finally, we 
will extend and further validate this risk prediction in the UKBiobank cohort as more 
precise individual level data and longer term follow up data become available. 
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Table 1. Colon cancer risk factors, its prevalence and reference information 
Risk factor Definition Male 
prevalence 
Female 
prevalence 
Source:  Population: 
1. Family history Brother, sister or 
parent had colon 
cancer (1st degree 
relatives affected 
with colon cancer). 
6.0% 7.0% Sandhu MS, Luben R, Khaw KT (2001) 
Prevalence and family history of colorectal 
cancer: implications for screening. J Med 
Screen 8(2): 69-72. 
30,353 participants aged 45-74 were 
recruited from GP between 1993 and 
1997 as part of the East Anglian 
component of the European 
Prospective Investigation into Cancer 
(EPIC–Norfolk). 
2. Obesity BMI≥27 kg/m2 52.0% 49.0% Health England survey 2013 (Micro data).  The 
Health Survey for England series was designed 
to monitor trends in the nation’s health, to 
estimate the proportion of people in England 
who have specified health conditions, and to 
estimate the prevalence of certain risk factors 
and combinations of risk factors associated 
with these conditions. 
UK population with a total of 2,362 
males and 2,810 females aged ≥45.   
3. Saturated fat milk or dairy 
products >=3 
serving/day  
9.0% 12.0% Findings from the National Adult Nutrition 
Survey: Dairy Intakes and Compliance with 
Food Pyramid Recommendations among Irish 
Adults Aged 65 years and over 
Irish population (database contain 
details data on servings, we selected 
high intake as >=3.5 servings/day). 
4. Alcohol More than 7 
servings per week 
59.0% 41.0% Health England survey 2013 (Micro data). UK population with a total of 2,362 
males and 2,810 females aged ≥45.  
Variable used for the analysis:  total 
unit of drinks per week. 
5. Vegetables  3 or more 
servings per day 
14.0% 14.0% Health England survey 2013 (Micro data). UK population with a total of 2,362 
males and 2,810 females aged ≥45.   
Variable used for the analysis: total 
portion of vegetable per day (adults 
aged 45+). 
6. Height 5 ft. 7 in or taller 10.0% 7.0% Health England survey 2013 (Micro data). UK population with a total of 2,362 
males and 2,810 females aged ≥45.   
Variable used for the analysis: valid 
height. 
Cancer Research. 
o
n
 June 2, 2017. © 2017 Am
erican Association for
ca
n
ce
rpreventionresearch.aacrjournals.org 
D
ow
nloaded from
 
Author m
anuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author M
anuscript Published O
nlineFirst on M
ay 30, 2017; DO
I: 10.1158/1940-6207.CAPR-16-0288 
19 
 
Risk factor Definition Male 
prevalence 
Female 
prevalence 
Source:  Population: 
7. Physical activity 3 or more hours 
total leisure-time 
physical activity 
per week. 
37.0% 23.0% Physical statistic 2015. Report by the British 
Heart Foundation Centre on Population 
Approaches for Non-Communicable Disease 
Prevention, Nuffield Department of Population 
Health, University of Oxford. 
UK population.  Guidelines issued by 
the Chief Medical Officers (CMOs) of 
England, Scotland, Wales and 
Northern Ireland in 2011.  Over a 
week, activity should add up to at 
least 150 minutes (2½ hours) of 
moderate intensity activity in bouts 
of 10 minutes or more. 
8. Red meat Eating 3 or more 
servings a week. 
(US meat one 
serving = 4 ounces 
or = 113.4 grams) 
97.5% 91.0% Parkin DM (2011) 5. Cancers attributable to 
dietary factors in the UK in 2010. II. Meat 
consumption. Br J Cancer 105 Suppl 2: S24-26. 
Data on consumption of meat in the 
UK year 2000–2001 from the 
National Diet and Nutrition Survey 
(Food Standards Agency, 2002) as 
mean consumption, in grams of 
different types of meat per week, by 
age group and sex. 
9. Use of birth 
control pills 
5 or more years of 
use 
N/A 57.0% Farrow A, Hull MGR, Northstone K, Taylor H, 
Ford WCL, Golding J (2002) Prolonged use of 
oral contraception before a planned pregnancy 
is associated with a decreased risk of delayed 
conception. Human Reproduction 17(10): 
2754-2761. 
The Avon Longitudinal Study of 
Parents and Children (ALSPAC). 
10. Use of 
postmenopausal 
hormones 
5 or more years of 
use 
 N/A 8.0% Benson VS, Kirichek O Fau - Beral V, Beral V 
Fau - Green J, Green J Menopausal hormone 
therapy and central nervous system tumor 
risk: large UK prospective study and meta-
analysis. (1097-0215 (Electronic)). 
UK population (General Practice 
Research Database (GPRD)). 
11. Aspirin use  Use daily for 15 
years of more. 
22.0% 13.0% Elwood P, Morgan G, White J, Dunstan F, 
Pickering J, Mitchell C, Fone D (2011) Aspirin 
taking in a south Wales county. The British 
Journal of Cardiology 18: 238-240. 
Sample of adults residing in the south 
Wales county of Caerphilly, the study 
conducted a survey of a sample 9,551 
adults resident in the county aged 
≥18 years. 
12. Multivitamin 
(folate) 
 folate intake 
reflected in 
regular 
multivitamin use 
(>15yrs vs no use) 
5.0% 7.0% Comparison of standardised dietary folate 
intake across ten countries participating in the 
European Prospective Investigation into 
Cancer and Nutrition. British Journal of 
Nutrition (2012), 108, 552–569. 
UK population
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Risk factor Definition Male 
prevalence 
Female 
prevalence 
Source:  Population: 
13. Inflammatory 
bowel disease 
 Affected by the 
condition for 10 or 
more years. 
1.0% 3.0% Canavan C, Card T, West J (2014) The incidence 
of other gastroenterological disease following 
diagnosis of irritable bowel syndrome in the 
UK: a cohort study. PLoS One 9(9): e106478. 
UK population (General Practice 
Research Database (GPRD)). 
14. Calcium 
supplement 
regular use of 
calcium 
supplement 
everyday 
11.0% 11.0% http://www.telegraph.co.uk/news/health/ne
ws/11900171/Calcium-supplements-dont-
work-say-experts.html 
UK population, up to 11 per cent of 
British adults are estimated take 
calcium supplements. 
16. Vitamin D 
supplement 
regular use of 
calcium 
supplement 
everyday 
15.0% 15.0% Spiro A and Buttriss J.L. (2014) Vitamin D:An
overview of vitamin D status and intake in 
Europe. Nutrition Bulletin Vol 39;4. 
Irish population
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Table 2. Relative risks for selected breast cancer risk factors extracted from the original publication by Colditz et al(14) and from the UKBiobank 
data 
Risk factor RR* RR** 95% C.I.** Score assigned in Colditz et al. Score assigned in the UKBiobank study 
Family history (mother and sister) 3.0 3.0  2.0 -3.6 25 25 
Family history (first-degree relative) 1.8 1.5 1.4-1.7 10 10 
Height  1.3 1.3 1.3-1.5 5 5 
Age of first period  0.8 0.9 0.9-1.0 -5 -5 
Age at menopause 1.2 1.3 1.2-1.4 5 5 
OC use 1.4 1.1 1.0-1.2 5 5 
Estrogen replacement ≥5years 1.7 1.3 1.2-1.4 10 5 
Estrogen replacement <5years 1.1 1.2 1.0-1.3 5 5 
Physical activity 0.6 0.9 0.8-0.9 10 5 
Alcohol 1.4 1.1 1.0-1.2 5 5 
Obesity (postmenopausal) 1.3 1.1 1.1-1.2 5 5 
Obesity (premenopausal) 0.8 0.8 0.8-1.0 -5 -5 
Multivitamin supplement 0.5 0.9 0.9-1.0 10 0 
No. of births 1.1 1.23 1.13-1.24 5 5 
Benign breast disease (MD diagnosed) 1.5 1.4 1.1-1.8 10 5 
birth weight 1.1 1.1 0.9-1.2 5 5 
*Relative risk from publication by Colditz et al, ** Relative risk from the UKBiobank study 
 
 
 
 
Cancer Research. 
o
n
 June 2, 2017. © 2017 Am
erican Association for
ca
n
ce
rpreventionresearch.aacrjournals.org 
D
ow
nloaded from
 
Author m
anuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author M
anuscript Published O
nlineFirst on M
ay 30, 2017; DO
I: 10.1158/1940-6207.CAPR-16-0288 
22 
 
Table 3. Risk score applied to level of relative risk     
Relative risk  Risk score
0.9 to < 1.1 0 
0.7 to < 0.9 or 1.1 to < 1.5 5 
0.4 to < 0.7 or 1.5 to < 3.0 10 
0.2 to < 0.4 or 3.0 to < 7.0 25 
< 0.2 or >=7.0  50 
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Table 4. Illustration of population average score and individual risk score for breast cancer 
Risk factor RR Description Score UK 
prevalence 
women 
Population 
average points 
for women 
Individual 
factor 
profile 
Individual 
score 
Family history 
(mother and sister) 
3.0 Two first degree relatives (mother and sister) affected 
with breast cancer before aged 65 
25 0.0011 0.03 No 0
Family history 
(first-degree relative) 
1.8 First degree relative who has a history of breast cancer 
before age 65 vs. none 
10 0.09 0.90 No 0
Height  1.3 5 feet 7 inch or taller for women 5 0.07 0.35 Yes 5
Age of first period  
 
0.8 Age of first period (15 vs.11)
 
-5 0.17 -0.85 Age 11 0
Age at menopause 1.2 Age at menopause (at the age of 55 or older) 5 0.07 0.34 Age 55 5
OC use 1.4 OC use (current use vs. none) 5 0.29 1.45 Yes 5
Oestrogen replacement 1.7 Oestrogen replacement>=5yrs 10 0.08 0.80 No 0
Oestrogen replacement 1.1 Oestrogen replacement <5yrs 5 0.08 0.40 No 0
Physical activity 0.6 3 or more hours total leisure-time physical activity per 
week 
10 0.77 7.70 No 10
Jewish heritage 1.2 Jewish heritage 5 0.005 0.03 No 0
Alcohol 1.4 More than 1 drink per day vs 0 5 0.41 2.05 Yes 5
Obesity 
(postmenopausal) 
1.3 27 kg/m2 or more 5 0.49 2.45 No 0
Obesity 
(premenopausal) 
0.8 27 kg/m2 or more -5 0.36 -1.80 Yes -5
Multivitamin 
supplement 
0.7 lack of use of multivitamin or B complex 5 0.73 7.3 Use vitamin 0
No. of births 1.1 No. of births (0 or 1 child) 5 0.24 1.20 No child 0
Benign breast disease 
(MD diagnosed) 
1.5 Benign breast disease (MD diagnosed)
 
10 0.13 1.30 No 0
Tamoxifen or raloxifene  0.5 tamoxifen or raloxifene for 5 years or more 10 0.30 3.0 No 10
Birth weight 1.1 birth weight >3.9kg or more 5 0.07 0.37 No 0
   Population 
average 
score 
27 Individual 
risk score 
35
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Table 5. Conversion of individual index score to single numeric factor 
individual index score   Level of risk   factor 
<0  Very much below average risk  0.2 
0, or < 0.5  Much below average risk  0.4 
0.5 < 0.9  Below average risk  0.7 
0.9 < 1.1  About average risk 1 
1.1 < 2.0  Above average risk 1.5 
2.0 < 5.0  Much above average risk  3 
5.0 or more times the average score  Very much above average risk 5 
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Table 6. 10-years estimated breast cancer risk in UK and US female population 
Age group 10-years estimated risk
UK females US females*
0-9 0.000% 0.00%
10-19 0.001% 0.00%
20-29 0.049% 0.06%
30-39 0.442% 0.44%
40-49 1.445% 1.44%
50-59 2.594% 2.28%
60-69 3.336% 3.46%
70-79 2.759% 3.89%
80+ 2.944% 3.02%
* Estimates from US SEER data 
Figure1. Model performance of the breast cancer sub-component of the model scored 
using binary factor categorisation: AUC and calibration curves 
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